Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody-mediated radiotherapy.

W D Bloomer, R Lipsztein, J F Dalton

    Cancer
    |May 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Antibodies targeting tumor cells offer cancer detection and therapy potential. Choosing the right radionuclide particle emitter is crucial for minimizing normal tissue damage and maximizing treatment efficacy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

    British journal of cancer·2010
    Same author

    Interaction of strong DNA-intercalating bioreductive compounds with topoisomerases I and II.

    Oncology research·2007
    Same author

    Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.

    Oncology research·2003
    Same author

    Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.

    Cancer chemotherapy and pharmacology·2002
    Same author

    Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.

    International journal of cancer·2001
    Same author

    In vitro evaluation of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-trifluoromethylquinoline hydrochloride (NLTQ-1), a new bioreductive agent as a hypoxia marker by 19F-magnetic resonance spectroscopy (19F-MRS).

    In vivo (Athens, Greece)·2001
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    See all related articles

    Area of Science:

    • Oncology
    • Radiochemistry
    • Immunotherapy

    Background:

    • Antibodies targeting tumor-specific antigens show promise for cancer detection and therapy.
    • Radiolabeling these antibodies could enable targeted radiation delivery for cancer treatment.
    • Key factors for effective radionuclide therapy include target specificity, high extraction, and retention time.

    Purpose of the Study:

    • To explore the potential of radiolabeled antibodies for cancer therapy.
    • To discuss the critical considerations in selecting appropriate radionuclides for antibody-based cancer treatments.
    • To evaluate different particle emitters (beta, Auger, alpha) for their efficacy and limitations in targeted cancer therapy.

    Main Methods:

    • Review of existing literature on radiolabeled antibodies in cancer research.

    Related Experiment Videos

  • Analysis of radionuclide properties, including particle emission type and energy deposition.
  • Evaluation of factors influencing therapeutic efficacy, such as antibody specificity and biodistribution.

    • Main Results:

    • Beta emitters have limited impact on disease outcome, except for thyroid cancer.
    • Auger emitters require close proximity to the genome for cytotoxicity.
    • Alpha emitters necessitate cell-specific localization but not subcellular sequestration.

    Conclusions:

    • The choice of radionuclide particle emitter is a critical, unanswered question in antibody-based cancer therapy.
    • Each particle emitter type (beta, Auger, alpha) presents unique advantages and challenges for targeted cancer treatment.
    • Further research is needed to optimize radionuclide selection for maximizing therapeutic benefit and minimizing off-target toxicity.